Novo Nordisk Falls as FDA Panel to Discuss Insulin Risks

Novo Nordisk has reported that U.S. regulators disclosed that an advisory panel on the company’s Tresiba diabetes treatment will focus on heart risks.

http://www.bloomberg.com/news/2012-10-25/novo-falls-in-u-s-as-fda-panel-to-discuss-insulin-risk.html